Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Metabolic Modeling of Pectobacterium parmentieri SCC3193 Provides Insights into Metabolic Pathways of Plant Pathogenic Bacteria.

Zoledowska S, Presta L, Fondi M, Decorosi F, Giovannetti L, Mengoni A, Lojkowska E.

Microorganisms. 2019 Apr 5;7(4). pii: E101. doi: 10.3390/microorganisms7040101.

2.

Genomic traits of Klebsiella oxytoca DSM 29614, an uncommon metal-nanoparticle producer strain isolated from acid mine drainages.

Gallo G, Presta L, Perrin E, Gallo M, Marchetto D, Puglia AM, Fani R, Baldi F.

BMC Microbiol. 2018 Nov 27;18(1):198. doi: 10.1186/s12866-018-1330-5.

3.

New Genome Sequence of an Echinaceapurpurea Endophyte, Arthrobacter sp. Strain EpSL27, Able To Inhibit Human-Opportunistic Pathogens.

Miceli E, Presta L, Maggini V, Fondi M, Bosi E, Chiellini C, Fagorzi C, Bogani P, Di Pilato V, Rossolini GM, Mengoni A, Firenzuoli F, Perrin E, Fani R.

Genome Announc. 2017 Jun 22;5(25). pii: e00565-17. doi: 10.1128/genomeA.00565-17.

4.

Constraint-based modeling identifies new putative targets to fight colistin-resistant A. baumannii infections.

Presta L, Bosi E, Mansouri L, Dijkshoorn L, Fani R, Fondi M.

Sci Rep. 2017 Jun 16;7(1):3706. doi: 10.1038/s41598-017-03416-2.

5.

Draft Genome Sequence of Pseudomonas sp. Strain Ep R1 Isolated from Echinacea purpurea Roots and Effective in the Growth Inhibition of Human Opportunistic Pathogens Belonging to the Burkholderia cepacia Complex.

Maggini V, Presta L, Miceli E, Fondi M, Bosi E, Chiellini C, Fagorzi C, Bogani P, Di Pilato V, Rossolini GM, Mengoni A, Firenzuoli F, Perrin E, Fani R.

Genome Announc. 2017 May 18;5(20). pii: e00351-17. doi: 10.1128/genomeA.00351-17.

6.

Phenotypic and genomic characterization of the antimicrobial producer Rheinheimera sp. EpRS3 isolated from the medicinal plant Echinacea purpurea: insights into its biotechnological relevance.

Presta L, Bosi E, Fondi M, Maida I, Perrin E, Miceli E, Maggini V, Bogani P, Firenzuoli F, Di Pilato V, Rossolini GM, Mengoni A, Fani R.

Res Microbiol. 2017 Apr;168(3):293-305. doi: 10.1016/j.resmic.2016.11.001. Epub 2016 Nov 22.

PMID:
27884784
7.

Modelling microbial metabolic rewiring during growth in a complex medium.

Fondi M, Bosi E, Presta L, Natoli D, Fani R.

BMC Genomics. 2016 Nov 24;17(1):970.

8.

Arthrobacter sp. EpRS66 and Arthrobacter sp. EpRS71: Draft Genome Sequences from Two Bacteria Isolated from Echinacea purpurea Rhizospheric Soil.

Presta L, Fondi M, Perrin E, Maida I, Miceli E, Chiellini C, Maggini V, Bogani P, Di Pilato V, Rossolini GM, Mengoni A, Fani R.

Front Microbiol. 2016 Sep 12;7:1417. doi: 10.3389/fmicb.2016.01417. eCollection 2016. No abstract available.

9.

Draft Genome Sequences of the Antimicrobial Producers Pseudomonas sp. TAA207 and Pseudomonas sp. TAD18 Isolated from Antarctic Sediments.

Presta L, Inzucchi I, Bosi E, Fondi M, Perrin E, Maida I, Miceli E, Tutino ML, Lo Giudice A, de Pascale D, Fani R.

Genome Announc. 2016 Jul 28;4(4). pii: e00728-16. doi: 10.1128/genomeA.00728-16.

10.

Draft Genome Sequence of Flavobacterium sp. Strain TAB 87, Able To Inhibit the Growth of Cystic Fibrosis Bacterial Pathogens Belonging to the Burkholderia cepacia Complex.

Presta L, Inzucchi I, Bosi E, Fondi M, Perrin E, Miceli E, Tutino ML, Lo Giudice A, de Pascale D, Fani R.

Genome Announc. 2016 May 19;4(3). pii: e00410-16. doi: 10.1128/genomeA.00410-16.

11.

Draft Genome Sequence of Pseudomonas sp. EpS/L25, Isolated from the Medicinal Plant Echinacea purpurea and Able To Synthesize Antimicrobial Compounds.

Presta L, Bosi E, Fondi M, Maida I, Perrin E, Miceli E, Maggini V, Bogani P, Firenzuoli F, Di Pilato V, Rossolini GM, Mengoni A, Fani R.

Genome Announc. 2016 May 5;4(3). pii: e00346-16. doi: 10.1128/genomeA.00346-16.

12.

Draft genome sequence and overview of the purple non sulfur bacterium Rhodopseudomonas palustris 42OL.

Adessi A, Spini G, Presta L, Mengoni A, Viti C, Giovannetti L, Fani R, De Philippis R.

Stand Genomic Sci. 2016 Mar 9;11:24. doi: 10.1186/s40793-016-0145-y. eCollection 2016.

13.

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, Wolchok JD.

Blood. 2014 Apr 3;123(14):2172-80. doi: 10.1182/blood-2013-12-544742. Epub 2014 Feb 20.

14.

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.

J Immunol Methods. 2011 Feb 28;365(1-2):132-41. doi: 10.1016/j.jim.2010.12.014. Epub 2010 Dec 23.

PMID:
21185301
15.

Molecular engineering and design of therapeutic antibodies.

Presta LG.

Curr Opin Immunol. 2008 Aug;20(4):460-70. doi: 10.1016/j.coi.2008.06.012. Review.

PMID:
18656541
16.

Evolving an anti-toxin antibody.

Presta L.

Nat Biotechnol. 2007 Jan;25(1):63-5. No abstract available.

PMID:
17211401
17.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC.

Int Immunol. 2006 Dec;18(12):1759-69. Epub 2006 Oct 31.

PMID:
17077181
18.

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.

Presta LG.

Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):640-56. Epub 2006 May 23. Review.

PMID:
16904789
19.

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ.

J Clin Invest. 2006 May;116(5):1317-26.

20.

Selection, design, and engineering of therapeutic antibodies.

Presta LG.

J Allergy Clin Immunol. 2005 Oct;116(4):731-6; quiz 737. Review.

PMID:
16210043
21.

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX.

Cancer Immunol Immunother. 2006 Jun;55(6):717-27. Epub 2005 Sep 3.

PMID:
16151804
22.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.

Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, Ling WL, Cannon-Carlson S, Greenberg R, Ramos RA, Shields R, Presta L, Brams P, Bishop WR, Pachter JA.

Mol Cancer Ther. 2005 Aug;4(8):1214-21.

23.

Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20.

Hong K, Presta LG, Lu Y, Penn A, Adams C, Chuntharapai A, Yang J, Wong WL, Meng YG.

J Immunol Methods. 2004 Nov;294(1-2):189-97. Epub 2004 Oct 6.

PMID:
15604027
24.

Antibody engineering for therapeutics.

Presta L.

Curr Opin Struct Biol. 2003 Aug;13(4):519-25. Review.

PMID:
12948783
25.

Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation.

Eigenbrot C, Meng YG, Krishnamurthy R, Lipari MT, Presta L, Devaux B, Wong T, Moran P, Bullens S, Kirchhofer D.

J Mol Biol. 2003 Aug 8;331(2):433-46.

PMID:
12888350
26.

Design, construction, and in vitro analyses of multivalent antibodies.

Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L.

J Immunol. 2003 May 1;170(9):4854-61.

27.

[Surgical complications following pancreaticoduodenectomy: results of a single center experience].

Molino D, Perrotti P, Napoli V, Antropoli C, Perrotta S, Presta L, Gargano E, Bocchetti R, D'Antonio D.

G Chir. 2002 Nov-Dec;23(11-12):405-12. Italian.

PMID:
12652913
28.

Celebrating diversity and mimicking maturation.

Presta LG.

Nat Biotechnol. 2002 Nov;20(11):1096-7. No abstract available.

PMID:
12410253
29.

Engineering therapeutic antibodies for improved function.

Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG.

Biochem Soc Trans. 2002 Aug;30(4):487-90. Review.

PMID:
12196120
30.

Engineering antibodies for therapy.

Presta LG.

Curr Pharm Biotechnol. 2002 Sep;3(3):237-56. Review.

PMID:
12164480
31.

Detection of Mirizzi syndrome with magnetic resonance cholangiopancreatography: laparoscopic or open approach?

Presta L, Ragozzino A, Perrotti P, Antropoli C, Molino D, De Ritis R, Mosca A.

Surg Endosc. 2002 Oct;16(10):1494-5. Epub 2002 Jul 8.

PMID:
12098030
32.

Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.

Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS.

J Mol Biol. 2002 Jul 5;320(2):415-28.

PMID:
12079396
33.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG.

J Biol Chem. 2002 Jul 26;277(30):26733-40. Epub 2002 May 1.

34.

Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule.

Gadek TR, Burdick DJ, McDowell RS, Stanley MS, Marsters JC Jr, Paris KJ, Oare DA, Reynolds ME, Ladner C, Zioncheck KA, Lee WP, Gribling P, Dennis MS, Skelton NJ, Tumas DB, Clark KR, Keating SM, Beresini MH, Tilley JW, Presta LG, Bodary SC.

Science. 2002 Feb 8;295(5557):1086-9.

35.

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hébert C, Zapata G.

Cytokine. 2001 Nov 7;16(3):106-19.

PMID:
11741351
36.
37.

Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE.

Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA.

Cytokine. 2001 Sep 7;15(5):250-60.

PMID:
11594789
38.

Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.

Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D.

Thromb Haemost. 2001 Mar;85(3):379-89.

PMID:
11307801
39.

Engineered antibodies with increased activity to recruit complement.

Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG.

J Immunol. 2001 Feb 15;166(4):2571-5.

40.

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.

Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG.

J Immunol. 2000 Apr 15;164(8):4178-84.

41.

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG.

J Biol Chem. 2001 Mar 2;276(9):6591-604. Epub 2000 Nov 28.

42.

Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients.

Poston RS, Robbins RC, Chan B, Simms P, Presta L, Jardieu P, Morris RE.

Transplantation. 2000 May 27;69(10):2005-13.

PMID:
10852588
43.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Clynes RA, Towers TL, Presta LG, Ravetch JV.

Nat Med. 2000 Apr;6(4):443-6.

PMID:
10742152
44.

TrkA amino acids controlling specificity for nerve growth factor.

O'Connell L, Hongo JA, Presta LG, Tsoulfas P.

J Biol Chem. 2000 Mar 17;275(11):7870-7.

45.
46.

Humanization of an antibody against human protein C and calcium-dependence involving framework residues.

O'Connor SJ, Meng YG, Rezaie AR, Presta LG.

Protein Eng. 1998 Apr;11(4):321-8.

PMID:
9680194
47.

An efficient route to human bispecific IgG.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P.

Nat Biotechnol. 1998 Jul;16(7):677-81.

PMID:
9661204
48.
50.

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N.

Cancer Res. 1997 Oct 15;57(20):4593-9.

Supplemental Content

Loading ...
Support Center